Icon (NASDAQ:ICLR) Director John Dr Climax Sells 5,005 Shares

Icon Plc (NASDAQ:ICLR) Director John Climax sold 5,005 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total transaction of $875,875.00. Following the completion of the transaction, the director owned 2,087 shares of the company’s stock, valued at $365,225. This represents a 70.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

John Dr Climax also recently made the following trade(s):

• On Tuesday, August 11th, John Climax sold 841 shares of Icon stock. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89.

Icon Trading Down 2.4%

Shares of Icon stock opened at $169.68 on Friday. Icon Plc has a 12-month low of $66.57 and a 12-month high of $203.91. The stock has a market cap of $12.99 billion, a PE ratio of 39.83, a price-to-earnings-growth ratio of 8.03 and a beta of 1.20. The company has a 50-day moving average of $167.27 and a two-hundred day moving average of $140.01. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. The business had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.26 earnings per share. On average, research analysts anticipate that Icon Plc will post 9.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Icon

A number of large investors have recently modified their holdings of the company. Franklin Resources Inc. raised its holdings in Icon by 8.7% in the fourth quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock valued at $545,410,000 after buying an additional 239,808 shares during the period. Principal Financial Group Inc. raised its stake in shares of Icon by 10.3% in the 1st quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock valued at $366,481,000 after acquiring an additional 310,236 shares during the period. Capital World Investors raised its stake in shares of Icon by 555.2% in the 4th quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock valued at $272,688,000 after acquiring an additional 1,268,095 shares during the period. Trinity Street Asset Management LLP lifted its holdings in shares of Icon by 27.1% during the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock valued at $266,725,000 after acquiring an additional 327,314 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. increased its holdings in Icon by 257.8% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock valued at $208,383,000 after purchasing an additional 864,300 shares in the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ICLR shares. Robert W. Baird set a $194.00 target price on Icon in a research report on Friday, July 31st. Leerink Partners set a $145.00 price objective on shares of Icon in a research note on Thursday, May 28th. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $126.00 to $185.00 in a report on Thursday, June 25th. DA Davidson set a $164.00 target price on shares of Icon in a research report on Monday, June 1st. Finally, Truist Financial restated a “buy” rating and issued a $209.00 target price (up from $207.00) on shares of Icon in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Icon has an average rating of “Hold” and an average price target of $170.40.

Icon Company Profile

ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.

Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence.